 | • レポートコード：GIR-22F19746 • 出版社/出版日：GlobalInfoResearch / 2022年11月 • レポート形態：英文、PDF、71ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Measles and Rubella (MR) Vaccine Market 2022」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社の最新の調査によると、世界の麻疹・風疹（MR）ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 麻疹・風疹（MR）ワクチン市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次をカバーします。 ・MRワクチン、MRBEVワクチン アプリケーション別セグメントは次のように区分されます。 ・民間流通経路、公共流通経路 世界の麻疹・風疹（MR）ワクチン市場の主要な市場プレーヤーは以下のとおりです。 ・PT Bio Farma、Bio-Manguinhos、BE Vaccines、Crucell Switzerland AG 地域別セグメントは次の地域・国をカバーします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、麻疹・風疹（MR）ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な麻疹・風疹（MR）ワクチンメーカーの企業概要、2019年～2022年までの麻疹・風疹（MR）ワクチンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な麻疹・風疹（MR）ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別麻疹・風疹（MR）ワクチンの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの麻疹・風疹（MR）ワクチンのタイプ別とアプリケーション別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での麻疹・風疹（MR）ワクチン市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および麻疹・風疹（MR）ワクチンの産業チェーンを掲載しています。 ・第13、14、15章では、麻疹・風疹（MR）ワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 麻疹・風疹（MR）ワクチンの概要 - タイプ別分析（2017年vs2021年vs2028年）：MRワクチン、MRBEVワクチン - アプリケーション別分析（2017年vs2021年vs2028年）：民間流通経路、公共流通経路 - 世界の麻疹・風疹（MR）ワクチン市場規模・予測 - 世界の麻疹・風疹（MR）ワクチン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - PT Bio Farma、Bio-Manguinhos、BE Vaccines、Crucell Switzerland AG ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：MRワクチン、MRBEVワクチン ・アプリケーション別分析2017年-2028年：民間流通経路、公共流通経路 ・麻疹・風疹（MR）ワクチンの北米市場分析 - 麻疹・風疹（MR）ワクチンの北米市場：タイプ別市場規模2017年-2028年 - 麻疹・風疹（MR）ワクチンの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・麻疹・風疹（MR）ワクチンのヨーロッパ市場分析 - ：麻疹・風疹（MR）ワクチンのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：麻疹・風疹（MR）ワクチンのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・麻疹・風疹（MR）ワクチンのアジア太平洋市場分析 - 麻疹・風疹（MR）ワクチンのアジア太平洋市場：タイプ別市場規模2017年-2028年 - 麻疹・風疹（MR）ワクチンのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・麻疹・風疹（MR）ワクチンの南米市場分析 - 麻疹・風疹（MR）ワクチンの南米市場：タイプ別市場規模2017年-2028年 - 麻疹・風疹（MR）ワクチンの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・麻疹・風疹（MR）ワクチンの中東・アフリカ市場分析 - 麻疹・風疹（MR）ワクチンの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 麻疹・風疹（MR）ワクチンの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Measles and Rubella (MR) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Measles and Rubella (MR) Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Private Distribution Channel accounting for % of the Measles and Rubella (MR) Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While MR Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Measles and Rubella (MR) Vaccine include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Crucell Switzerland AG, and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Measles and Rubella (MR) Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
MR Vaccine
MRBEV Vaccine
Market segment by Application can be divided into
Private Distribution Channel
Public Distribution Channel
The key market players for global Measles and Rubella (MR) Vaccine market are listed below:
PT Bio Farma
Bio-Manguinhos
BE Vaccines
Crucell Switzerland AG
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Measles and Rubella (MR) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Measles and Rubella (MR) Vaccine, with price, sales, revenue and global market share of Measles and Rubella (MR) Vaccine from 2019 to 2022.
Chapter 3, the Measles and Rubella (MR) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Measles and Rubella (MR) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Measles and Rubella (MR) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Measles and Rubella (MR) Vaccine.
Chapter 13, 14, and 15, to describe Measles and Rubella (MR) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Measles and Rubella (MR) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Measles and Rubella (MR) Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 MR Vaccine
1.2.3 MRBEV Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Measles and Rubella (MR) Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Private Distribution Channel
1.3.3 Public Distribution Channel
1.4 Global Measles and Rubella (MR) Vaccine Market Size & Forecast
1.4.1 Global Measles and Rubella (MR) Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Measles and Rubella (MR) Vaccine Sales in Volume (2017-2028)
1.4.3 Global Measles and Rubella (MR) Vaccine Price (2017-2028)
1.5 Global Measles and Rubella (MR) Vaccine Production Capacity Analysis
1.5.1 Global Measles and Rubella (MR) Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Measles and Rubella (MR) Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Measles and Rubella (MR) Vaccine Market Drivers
1.6.2 Measles and Rubella (MR) Vaccine Market Restraints
1.6.3 Measles and Rubella (MR) Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 PT Bio Farma
2.1.1 PT Bio Farma Details
2.1.2 PT Bio Farma Major Business
2.1.3 PT Bio Farma Measles and Rubella (MR) Vaccine Product and Services
2.1.4 PT Bio Farma Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Bio-Manguinhos
2.2.1 Bio-Manguinhos Details
2.2.2 Bio-Manguinhos Major Business
2.2.3 Bio-Manguinhos Measles and Rubella (MR) Vaccine Product and Services
2.2.4 Bio-Manguinhos Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 BE Vaccines
2.3.1 BE Vaccines Details
2.3.2 BE Vaccines Major Business
2.3.3 BE Vaccines Measles and Rubella (MR) Vaccine Product and Services
2.3.4 BE Vaccines Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Crucell Switzerland AG
2.4.1 Crucell Switzerland AG Details
2.4.2 Crucell Switzerland AG Major Business
2.4.3 Crucell Switzerland AG Measles and Rubella (MR) Vaccine Product and Services
2.4.4 Crucell Switzerland AG Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Measles and Rubella (MR) Vaccine Breakdown Data by Manufacturer
3.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Measles and Rubella (MR) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Measles and Rubella (MR) Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Measles and Rubella (MR) Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Measles and Rubella (MR) Vaccine Manufacturer Market Share in 2021
3.5 Global Measles and Rubella (MR) Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Measles and Rubella (MR) Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Measles and Rubella (MR) Vaccine Market Size by Region
4.1.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Measles and Rubella (MR) Vaccine Revenue by Region (2017-2028)
4.2 North America Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.3 Europe Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.5 South America Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Measles and Rubella (MR) Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Measles and Rubella (MR) Vaccine Revenue by Type (2017-2028)
5.3 Global Measles and Rubella (MR) Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Measles and Rubella (MR) Vaccine Revenue by Application (2017-2028)
6.3 Global Measles and Rubella (MR) Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
7.2 North America Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
7.3 North America Measles and Rubella (MR) Vaccine Market Size by Country
7.3.1 North America Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
8.2 Europe Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
8.3 Europe Measles and Rubella (MR) Vaccine Market Size by Country
8.3.1 Europe Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Measles and Rubella (MR) Vaccine Market Size by Region
9.3.1 Asia-Pacific Measles and Rubella (MR) Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Measles and Rubella (MR) Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
10.2 South America Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
10.3 South America Measles and Rubella (MR) Vaccine Market Size by Country
10.3.1 South America Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Measles and Rubella (MR) Vaccine Market Size by Country
11.3.1 Middle East & Africa Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Measles and Rubella (MR) Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Measles and Rubella (MR) Vaccine
12.3 Measles and Rubella (MR) Vaccine Production Process
12.4 Measles and Rubella (MR) Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Measles and Rubella (MR) Vaccine Typical Distributors
13.3 Measles and Rubella (MR) Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer